A review of the use of exemestane in early breast cancer

Therapeutics and Clinical Risk Management

Volumn 5, Issue 1, 2009, Pages 91-98

  Robinson, Andrew ^a  

^a NORTHERN ONTARIO SCHOOL OF MEDICINE   (Canada)

Author keywords

Adjuvant; Breast cancer; Exemestane

Indexed keywords

AROMATASE INHIBITOR; EXEMESTANE; TAMOXIFEN;

ARTHRALGIA; BREAST CANCER; CANCER RECURRENCE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED STUDY; EARLY CANCER; HOT FLUSH; HUMAN; MYALGIA; PATIENT COMPLIANCE; POSTMENOPAUSE; QUALITY OF LIFE; RECURRENCE RISK; REVIEW; RISK REDUCTION; THROMBOEMBOLISM; VAGINA BLEEDING; VENOUS THROMBOEMBOLISM;

EID: 77949468258     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Parkin D, Bray F, Ferlay J, Pisani P. Global Cancer Statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
2. Joslyn SA. Hormone receptors in breast cancer: racial differences in distribution and survival. Breast Cancer Res Treat. 2002;73:45-59.
3. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365: 1687-1717.
4. Beatson GW. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet. 1896;148(3802):104-107.
5. Huggins C, Dao TL. Adrenalectomy and oophorectomy in treatment of advanced carcinoma of the breast. JAMA. 1953;151:1388-1394.
6. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in post-menopausal women with primary breast cancer. N Engl J Med. 2004;350:1081-1092.
7. Zilembo N, Noberasco C, Bajetta E, Martinetti A, Mariani L, Orefici S. Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor. Br J Cancer. 1995;72:1007-1012.
8. Spinelli R, Jannuzzo MG, Poggesi I, Frevola L, Broutin F, Cicioni P. Pharmacokinetics (PK) of Aromasin (Exemestane, EXE) after single and repeated doses in healthy postmenopausal volunteers (HPV). Eur J Cancer. 1999;35 suppl 4:S295.
9. Anonymous. Exemestane for advanced breast cancer. Med Lett Drugs Ther. 2000;42:35-36.
10. Dixon JM, Grattage L, Renshaw L, Miller WR. Exemestane as neoadjuvant treatment for locally advanced breast cancer: endocrinologic and clinical endpoints. Breast Cancer Res Treat. 2000;64:53.
11. Jannuzzo M, Di Salle E, Spinelli R, et al. Estrogen suppression in premenopausal women following 8 weeks of treatment with exemestane and triptorelin versus triptorelin alone. Breast Cancer Res Treat. 2008. [Epub ahead of print].
12. Coombes RC, Kilburn LS, Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet. 2007;369(9561):559.
13. Jones, SE. Exemestane as adjuvant treatment of early breast cancer: intergroup exemestane study/tamoxifen exemestane adjuvant multicenter trials. Clin Breast Cancer. 2006;6 suppl 2:S41-S44.
14. Mamounas EP, Jeong J-H, Wickerham DL, et al. Benefit from exemestane as extended adjuvant therapy following five years of adjuvant tamoxifen: Intent-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 Trial. J Clin Oncol. 2008;26:1965-1971.
15. Dellapasqua S, Colleoni M, Gelber R, Goldhirsh A. Adjuvant endocrine therapy for premenopausal women with early breast cancer. J Clin Oncol. 2005;26:1736-1750.
16. Takei H, Suemasu K, Inoue K, et al. Multicenter phase II trial of neoadjuvant exemestane for postmenopausal patients with hormone receptor-positive, operable breast cancer: Saitama Breast Cancer Clinical Study Group (SBCCSG-03). Breast Cancer Res Treat. 2008;107:87-94.
17. Tubiani Hulin M, Becette V, Bieche I, et al. Exemestane as neoadjuvant hormonotherapy for locally advanced breast cancer: results of a phase II trial. Anticancer Res. 2007;27:2689-2696.
18. Mlineritsch B, Tausch C, Singer C, et al. Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17). Breast Cancer Res Treat. 2007. [Epub ahead of print].
19. Smith IE, Dowsett M, Yap YS, et al. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. J Clin Oncol. 2006;24:2444-2447.
20. Deitcher SR, Gomes SP. The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review. Cancer. 2004;101(3):439-449.
21. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet. 2002;359(9319):1761-1767.
22. Fisher B, Constantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90(18):1371-1388.
23. Cooke AL, Metge C, Lix L, Prior HJ, Leslie WD. Tamoxifen use and osteoporotic fracture risk - A population based analysis. J Clin Oncol. 2008; Epub October 6.
24. Ding H, Field TS. Bone health in postmenopausal women with early breast cancer: how protective is tamoxifen? Cancer Treat Rev. 2007;33(6):506-513.
25. Coleman RE, Banks LM, Girgis IS, et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol. 2007;8(2):119-127.
26. Kessel B. Hip fracture prevention in postmenopausal women. Obstet Gynecol Surv. 2004;59(6):446-455.
27. Markopolous C, Polychronis A, Zobolas V, et al. The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study. Breast Cancer Res Treat. 2005;93(1):61-66.
28. Rutqvist LE, Johansson H, et al. Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer. Acta Oncol. 2007;46(2):133-145.
29. Fallowfield L, Bliss J, Porter L, et al. Quality of life in the Intergroup Exemestane Study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol. 2006;24:910-917.
30. Jones SE, Cantrell J, Vukelja S, et al. Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudy. J Clin Oncol. 2007;25(30):4765-4771.
31. Derzko C, Elliott S, Lam W. Management of sexual dysfunction in postmenopausal breast cancer patients taking adjuvant aromatase inhibitor therapy. Curr Oncol. 2007;14 Suppl 1:S20-S40.
32. Kendall A, Dowsett M, Folkerd E, Smith I. Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol. 2006;17(4):584-587.
33. Mok K, Juraskova I, Friedlander M. The impact of aromatase inhibitors on sexual functioning: Current knowledge and future research directions. Breast. 2008 May 12 [epub ahead of print].
34. Presant CA, Bosserman L, Young T, et al. Aromatase inhibitor-associated arthralgia and/ or bone pain: frequency and characterization in non-clinical trial patients. Clin Breast Cancer. 2007;7(10):775-778.
35. Morales L, Pans S, Verschueren K, et al. Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome. J Clin Oncol. 2008 May 12 [Epub ahead of print].
36. Cella D, Fallowfield LJ. Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy. Breast Cancer Res Treat. 2008;107(2):167-180.
37. Francheschi M, Scarcelli M, Niro V, et al. Prevalence, clinical features and avoidability of adverse drug reactions as cause of admission to a geriatric unit: a prospective study of 1756 patients. Drug Saf. 2008;31(6):545-556.
38. Cirillo DJ, Wallace RB, Wu L, Yood RA. Effect of hormone therapy on risk of hip and knee joint replacement in the Women's Health Initiative. Arthritis Rheum. 2006;54(10):3194-3120.
39. Thomas R, Williams M, Marshall C, Walker L. Switching to letrozole or exemestane improves hot flushes, mood and quality of life in tamoxifen intolerant women. Br J Cancer. 2008;98:1494-1499.